Shares in Teva Pharmaceuticals (NYSE:TEVA) climbed 12% this morning after the company announced it plans to cut more than a quarter of its global workforce, suspend its dividend and shut down research facilities and factories. The drug-maker, which appointed a new CEO and management team this year, is looking to restructure and pay down debt. “Two […]
Featured
Companion Medical launches smart insulin pen in U.S.
Companion Medical started selling its smart insulin pen in the U.S. today, according to the San Diego, Calif.-based company. The InPen system, which combines an insulin injector pen and a smartphone app, is compatible with Eli Lilly‘s (NYSE:LLY) Humalog and Novo Nordisk‘s (NYSE:NVO) Novolog fast-acting insulin. Companion Medical’s InPen tracks insulin dosing, automatically sending data […]
Shire taps Rani Therapeutics’ oral delivery tech for hemophilia therapy
Shire (NSDQ:SHPG) said this week that it is collaborating with Rani Therapeutics to combine the company’s Rani Pill technology for the delivery of factor VIII therapy in patients with hemophilia A. According to the terms of the deal, Shire has the exclusive option to negotiate a license to develop and commercialize the technology as a delivery […]
Appeal board to review Sanofi’s Lantus insulin injection patents
The U.S. Patent and Trademark Appeal Board has instituted inter partes review on all claims against two patents owned by Sanofi (NYSE:SNY) for the company’s Lantus insulin glargine injection. Sanofi filed a patent infringement suit against Mylan (NSDQ:MYL) in October after the EpiPen-maker submitted an NDA for a pre-filled insulin glargine pen, challenging the patents listed for Sanofi’s Lantus […]
FDA approves Sanofi’s short-acting insulin lispro injection
The FDA today approved Sanofi‘s (NYSE:SNY) Admelog insulin lispro injection. The product is indicated to help adults and kids with Type I and Type II diabetes control their blood sugar levels. Admelog is the first short-acting insulin approved using the FDA’s 505(b)(2) pathway. “One of my key policy efforts is increasing competition in the market […]
Intersect ENT wins FDA nod for Sinuva polyp-disease-treating sinus implant
Intersect ENT (NSDQ:XENT) said today it won FDA approval for its Sinuva mometasone furoate sinus implant designed to treat recurrent nasal polyp disease in patients who have previously had ethmoid sinus surgery. The Sinuva device is designed to be implanted during a routine physician office visit and expands into the sinus cavity to deliver an anti-inflammatory steroid […]
Medtech stories we missed this week: Dec. 8, 2017
From Minimus Spine’s European distribution deal to Stimwave receiving FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Minimus Spine inks EU distribution deal Minimus Spine announced in a Dec. 4 press release that it has signed its first European distribution deal with Italian company Moss […]
Novo Nordisk inks outcomes-based contract with pharmacy benefit manager for Victoza
Novo Nordisk (NYSE:NVO) said today that it inked a value-based contract for its Type II diabetes drug, Victoza, with pharmacy benefit manager Prime Therapeutics. The agreement is part of Prime’s CareCentered Contract program. Under the terms of the deal, Prime will evaluate Victoza’s efficacy and will reimburse commercial clients if certain measures aren’t met, according to the company. […]
Novaliq’s NovaTears, Omega-3 combo approved in Europe for evaporative dry eye disease
Privately-held pharma company Novaliq GmbH said this week that its NovaTears+Omega-3 combo therapy for patients with evaporative dry disease was registered in Europe. The treatment uses Novaliq’s water-free EyeSol drug delivery tech and is available in a multi-dose bottle. The company touted its product as the first eye drop to contain high concentrations of Omega-3 […]
Tandem’s finance chief to retire at year’s end | Personnel Moves – Dec. 8, 2017
Tandem Diabetes Care (NSDQ:TNDM) announced today that its EVP and chief financial exec, John Cajigas, will retire at the end of 2017. The company’s SVP of finance, Leigh Vosseller, is slated to take his place effective Jan. 1. Tandem noted that Cajigas’ retirement is not due to any disagreement or problem with the company’s accounting or […]